일라이 릴리의 Tirzepatide, 임상 3상에서 심부전 위험 38% 감소

Category

임상시험/파이프라인

Type

Success

Official Announcement

https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-successful-phase-3-study-showing-benefit

BioPharma Dive

https://www.biopharmadive.com/news/lilly-zepbound-heart-failure-glp-1-study-results/723058/

BioSpace

https://www.biospace.com/drug-development/lillys-tirzepatide-clears-phase-iii-cardiovascular-study-on-heels-of-novo

Firstword

https://firstwordpharma.com/story/5881214

Fierce Group

https://www.fiercepharma.com/pharma/eli-lilly-after-tirzepatides-late-stage-cardio-trial-win-plots-regulatory-filings-year

Release Date

2024/08/05

14 more properties

한글종합기사

Official Announcement

BioPharma Dive

BioSpace

Firstword

Fierce Group